Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 5.3% on Insider Buying Activity

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price shot up 5.3% during mid-day trading on Tuesday after an insider bought additional shares in the company. The company traded as high as $20.54 and last traded at $20.18. 20,155 shares were traded during mid-day trading, a decline of 90% from the average session volume of 200,547 shares. The stock had previously closed at $19.17.

Specifically, Director Robert W. Duggan bought 55,256 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The shares were bought at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the transaction, the director now directly owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. This trade represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Robert W. Duggan purchased 56,054 shares of the company’s stock in a transaction on Wednesday, December 11th. The stock was acquired at an average cost of $17.35 per share, for a total transaction of $972,536.90. Following the completion of the purchase, the director now owns 42,228,057 shares of the company’s stock, valued at approximately $732,656,788.95. This trade represents a 0.13 % increase in their position. The disclosure for this purchase can be found here.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research note on Thursday, December 12th.

Pulse Biosciences Trading Down 7.3 %

The stock’s 50-day moving average price is $17.85 and its 200-day moving average price is $16.56.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter in the previous year, the business earned ($0.19) earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PLSE. Bank of New York Mellon Corp raised its stake in shares of Pulse Biosciences by 23.4% in the second quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after purchasing an additional 9,639 shares during the last quarter. Rhumbline Advisers raised its position in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after buying an additional 1,608 shares during the last quarter. Quest Partners LLC bought a new position in Pulse Biosciences during the 2nd quarter valued at $91,000. Creative Planning lifted its stake in Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after acquiring an additional 11,667 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Pulse Biosciences by 193.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after acquiring an additional 97,565 shares during the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.